Immuno-Biological Laboratories Co 4570.T · JPY
Health Care · Tokyo Stock Exchange · 🇯🇵 Japan
927
+1.31%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Immuno-Biological Laboratories Co
Its shares trade on Tokyo Stock Exchange under the ticker 4570.T. It has been listed since 2 March 2007. In the fiscal year to 31 March 2026, it reported revenue of ¥1.00bn and net income of ¥329.0m. At that date it held total assets of ¥2.16bn and shareholders' equity of ¥1.84bn.
Immuno-Biological Laboratories Co., Ltd. engages in the manufacture and sale of antibody-related reagents and pharmaceutical products. The company is headquartered in Fujioka-Shi, Gumma-Ken(Gunma-Ken). The company went IPO on 2007-03-02. The firm operates in four business segments. The Diagnostic and Reagent segment is engaged in the manufacture, purchase and sales of research-related reagents, medicine, as well as vitro diagnostics. The Genetically Modified Silkworm segment is engaged in the sales of transgenic silkworm cocoons related products and research development of pharmaceutical raw materials. The Testing segment is engaged in the provision of support for prevention and diagnosis in addition to drug discovery and research support in the field of lifestyle-related diseases using lipid metabolism analysis technology. The Cosmetics segment is engaged in the sales of cosmetics and other products.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 2 Mar 2007
- Employees
- 60
- Website
- ibl-japan.co.jp ↗
Leadership
Pay as last reported
- Mr. Tsutomu SeitoPresident, Representative Director, since 2021
- Mr. Masato NakagawaManaging Director, Chief Director of Business Group Administration, since 2008
- Ms. Shoko OnoderaDirector of Human Resources and General Affairs, Manager of Internal Audit Office, President of Subsidiary, Director, since 2008
- Mr. Daisuke KawaseExecutive Officer
- Mr. Tatsuya SegawaExecutive Officer
- Mr. Masahiro TomitaExecutive Officer, since 2013
- Ms. Ayano TsuburayaExecutive Officer
- Dr. Masahiro MaedaChief Director of Antibody-Related Business, Director of Clinical Testing Business, Director, since 2007
- Mr. Kenji FukunagaIndependent Director
- Mr. Ikkei KojimaIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Manufactures antibody-related reagents and pharmaceutical products in Japan.
- Operates four business segments including diagnostics and cosmetics.
- Employs 60 full-time employees with a focus on research and development.
Weaknesses
- Limited to four business segments with no expansion mentioned.
- No mention of international market presence or global reach.
- Relies on silkworm-based products for pharmaceutical raw materials.
Opportunities
- Expanding into global markets for antibody reagents and diagnostics.
- Growing demand for lifestyle-related disease research support services.
- Increasing cosmetic market in Japan for product sales.
Threats
- Competition from larger pharmaceutical companies in Japan.
- Regulatory changes affecting silkworm-based pharmaceutical raw materials.
- Economic downturns impacting healthcare and cosmetic spending.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.